Antiretroviral-associated liver injury

Clinics in Liver Disease

Volumn 7, Issue 2, 2003, Pages 475-499

  Ogedegbe, Anthony O ^a   Sulkowski, Mark S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

COMORBIDITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER INJURY; LIVER TOXICITY; LONG TERM CARE; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

EID: 0038385190     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00023-0     Document Type: Review

References (195)

1. Styrt B, Freiman JP. Hepatotoxicity of antiviral agents. Gastroenterol Clin N Am 1995;24:839-52.
2. Hayden FG. Antiviral agents. In: Mandel GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th edition. New York: Churchill Livingstone; 2000. p. 460-91.
3. Hanna GJ, Hirsch MS. Antiviral agents. In: Mandel GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th edition. New York: Churchill Livingstone; 2000. p. 1479-500.
4. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for the hepatologist? J Hepatol 2002;36:283-94.
5. Palella FJ, Delaney KM, Moorman AC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J of Med 1998;338:853-60.
6. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
7. Fellay J, Boubaker K, Ledergerber B. Prevalence of adverse events associated with potent antiretroviral treatment. Swiss HIV Cohort Study. Lancet 2001;358:1322-7.
8. Carr A. Improvements of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 2002;360:81-5.
9. Powderly WG. Long-term exposure to life-long therapies. J Acquir Immune Defic Syndr 2002;360:S28-40.
10. Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS 2002;16:737-45.
11. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
12. Van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993;9:255-62.
13. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore. Maryland. J Clin Microbiol 1997;35:3274-7.
14. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74:212-20.
15. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis 2002;34:831-7.
16. Zenilman JM, Hook EW, Shepherd M, Smith P, Rompalo AM, Celentano DD. Alcohol and other substance use in STD clinic patients: relationships with STDs and prevalent HIV infection. Sex Transm Dis 1994;21:220-5.
17. Latkin CA, Mandell W, Vlahov D. The relationship between risk networks' patterns of crack cocaine and alcohol consumption and HIV-related sexual behaviors among adult injection drug users: a prospective study. Drug Alcohol Depend 1996;42:175-81.
18. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002;97:2071-8.
19. Wong JK, Hezarch M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
20. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7.
21. Farrell GC. Liver disease caused by drugs, anesthetics, and toxins. In: Feldman M, Sleisenger MH, Fordtran JS, editors. Gastrointestinal and Liver Disease. 6th edition. W.B. Saunders Company; 1998. p. 1221-52.
22. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitainc Cohort, France, 1996-98. AIDS 1999;13:F115-21.
23. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
24. Gisolf EH, Dreezen C, Danner SA, Weel JLF, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis 2000;31:1234-9.
25. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2000;44:3451-5.
26. den Brinker M, Wit FW, Wertheim van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hcpatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-902.
27. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-31.
28. D'Arminio Montforte A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114-23.
29. Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-8.
30. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
31. Boxwell D, Haverkos H, Kukich S, et al. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-Worldwide, 1997-2000. Morb Mortal Wkly Rep 2001;49:1153-6.
32. Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res 1996;31:121-35.
33. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-55.
34. Welch K, Finkbeiner W, Alpers CE, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA 1984;252:1152-9.
35. Lebovics E, Thung SN, Schaffner F, Radensky PW. The liver in the acquired immunodeficiency syndrome: a clinical and histologic study. Hepatology 1985;5:293-8.
36. Nakanuma Y, Liew CT, Peters RL, Govindarajan S. Pathologic features of the liver in acquired immune deficiency syndrome (AIDS). Liver 1986;6:158-66.
37. Kahn SA, Saltzman BR, Klein RS, et al. Hepatic disorders in the acquired immune deficiency syndrome: a clinical and pathological study. Am J Gastrol 1986;12:1145-8.
38. Bach N, Thcisc ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis 1992;12:205-12.
39. Lefkowitch JH. The liver in AIDS. Semin Liver Dis 1997;17:335-44.
40. Dworkin BM, Stahl RE, Giardina MA, et al. The liver in acquired immune deficiency syndrome: emphasis on patients with intravenous drug abuse. Am J Gastroenterol 1987;82:231-6.
41. Schneiderman DJ, Arenson DM, Cello JP, et al. Hepatic disease in patients with acquired immune deficiency syndrome. Hepatology 1987;7:925-30.
42. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995;123:933-6.
43. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco 1994-1998. J Infects Dis 2002;186:1023-7.
44. Selik RM, Byers RH, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection. J Acquir Immune Defic Syndr 2002;24:378-87.
45. Kelly JW, Dooley DP, Lattuada CP, Smith CE. A severe, unusual reaction to trimetboprimsulfamethoxazole in patients infected with human immunodeficiency virus. Clin Infect Dis 1992;14:1034-9.
46. Melamed AJ, Muller RJ, Gold JWM, Wise Campbell S, Kleinberg ML, Armstrong D. Possible zidovudine-induced hepatotoxicity. JAMA 1987;258:2063.
47. Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. Ann Intern Med 1989;110:85-6.
48. Lai KK, Gang D, Zawacki J, Cooley T Fulminant hepatic failure associated with 2′,3′-dideoxyinosine. Ann Intern Med 1991;115:283-4.
49. Shintaku M, Nasu K, Shimizu T. Fulminant hepatic failure in an AIDS patient: possible zidovudine-induced hepatotoxicity. Am J Gastroenterol 1993;88:464-6.
50. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993;7:379-85.
51. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
52. Bissuel F, Bruneel F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994;235:367-71.
53. Matsuda J, Gohchi K, Yamanaka M. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet 1997;350:364.
54. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997;349:924-5.
55. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995-6.
56. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998;12:1722-4.
57. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998;12:116-7.
58. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998;12:1256.
59. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998;12:2289-93.
60. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-91.
61. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-7.
62. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of azidothymidine in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 Infection. Ann Intern Med 1990;112:727-37.
63. Lambert JS, Seidlin M, Reichman RC, et al. 2′-3′-dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1340-5.
64. Cooley TP, Kunches LM, Saunders CA, et al. Once daily administration of 2′,3′-dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N Engl J Med 1990;322:1340-5.
65. Schindzierlorz A, Pike I, Daniels M, Pacelli Smaldone L. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis 1994;19:1076-83.
66. Browne MJ, Mayer KH, Chafee BD, et al. 2′,3′-Didehydro-3′-deoxythymidine in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993;167:21-9.
67. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995;17(Suppl 2):S123-30.
68. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995;171(Suppl 2):S131-9.
69. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995;171(Suppl 2):S113-7.
70. Van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-5.
71. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination in antiretroviral treatment-naïve patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25.
72. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naïve subjects. AIDS 1998;12:F197-202.
73. Saag MS, Sonnerborg A, Torres RA, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998;12:F203-9.
74. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmokinetics of abacavir (1592U89) following oral administration of escalating doses in human immunodeficiency virus HIV-infected adults. Antimicrob Agents Chemother 1999;43:603-8.
75. Staszewski S, Keiscr P, Montaner J, et al. Abacavir-lamivudine-zidovudine versus indinavirlamivudine-zidovudine in antiretroviral-naïve adults. JAMA 2001;9:1155-63.
76. Kessler HA, Johnson J, Follansbee S, et al. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. Clin Infect Dis 2002;34:535-42.
77. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenenine, a novel anti-human immunodeficiency virus therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998;42:2380-4.
78. Barditch-Crovo P, Deeks SG, Collier A, et al. phase I/II trial of pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
79. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000;30:198-200.
80. Miller K, Cameron M, Wood L, Dalakas M, Kovacs J. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133:192-6.
81. Coghlan ME, Sommadossi J-P, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001;33:1914-21.
82. Gerad Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-30.
83. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-6.
84. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23.
85. Boubaker K, Flepp M, Sudre P, et al. Hyper-lactatemia and antiretroviral therapy: the Swiss HIV cohort Study. Clin Infect Dis 2001;33:1931-7.
86. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30:156-60.
87. Bleeker-Rovers CP, Kadir SW, van Leusen R, Richter C. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 2000;57:190-3.
88. Johri S, Alkuja S, Siviglia G, Soni A. Steatosis lactic acidosis syndrome associated with stavudine and lamivudine therapy. AIDS 2000;14:1286-7.
89. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-46.
90. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
91. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60.
92. Chen X, Goudsmit J, Van der Kuyl A. Lack of correlation between length variation in the DNA polymerase γ gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. AIDS Res Hum Retroviruses 2002;18:531-4.
93. Morris AAM, Taanman J-W, Blake J, et al. Liver failure associated with mitochondrial DNA depletion. J Hepatol 1998;28:556-63.
94. Mandel H, Hartman C, Berkowitz D, Elpeleg ON, Manov I, Iancu TC. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 2001;34:776-84.
95. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22.
96. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Inf 2001;77:158-73.
97. Simpson MV, Chin CD, Keilbaugh SA, Lin T-S, Prusoff WH. Studies on the inhibition of mitochondrial DNA-replication by 3′-azido-3′deoxythymidine and other dideoxynueleoside analogs which inhibit HIV-1 replication. Biochem Pharmacol 1989;38:1033-6.
98. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989;255:11847-52.
99. Chen C, Vasquez-Padua M, Cheng Y. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-8.
100. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23.
101. Johnson A, Ray A, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-57.
102. Corcuera T, Alonso MJ, Picazo A, et al. Hepatic Morphological alterations induced by zidovudine in an experimental model. Pathol Res Pract 1996;192:182-7.
103. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine- induced toxicity. N Engl J Med 1990;322:1098-105.
104. Amaudo E, Dalakas M, Shanske S, Morales CT, DiMauro S, Schon EA. Depletion of muscle mitochondria DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-10.
105. Mhiri C, Baudrimont M, Bonne G, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991;29:606-14.
106. Gopinath R, Hutcheon M, Cheema-Dhadli S, Halperin M. Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: Biochemical studies. J Am Soc Nephrol 1992;3:1212-9.
107. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-7.
108. Cote HCF, Brumme ZL, Craib JP, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
109. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: contribution to PI-related LD syndrome. AIDS 2000;14:F25-32.
110. Sven AD, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl Med 1995;23:1528-33.
111. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
112. Stein DS, Fish DG, Billelo JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
113. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
114. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
115. Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997;41:2428-32.
116. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-7.
117. Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS 1998;12: F103-9.
118. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998;177:1533-40.
119. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998;38:736-43.
120. Haubrich R, Thompson M, Schooley R, et al. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS 1999;13:2411-20.
121. Evon JJ, Haubrich R, Lang W, Pagano G, et al. A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir or saquinavir. J Acquir Immune Defic Syndr 2001;26:458-61.
122. Murphy RL, Brun S, Hicks C, Eron JJ, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001;15:F1-9.
123. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
124. Walmsley S, Bemstein B, King M, Arribas J, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46.
125. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002;36:1193-203.
126. Michelet C, Ruffault A, Sebille V, et al. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001;45:3393-402.
127. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-63.
128. Hammer SM, Vaida F, Bennett KK, et al. Dual versus single protease inhibitor therapy following antiretroviral treatment failure. JAMA 2002;288:169-80.
129. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001;276:37514-9.
130. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998;177:783-5.
131. Zylberberg H, Chaix ML, Rabian C, Rouzioux C, Aulong B, Brechot C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998;26:1104-6.
132. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002;16:1915-23.
133. Laskus T, Radkowski M, Piasek A, et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000;181:442-8.
134. Crovatto M, Pozzato G, Zorat F, et al. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus. Haematologica 2000;85:356-61.
135. Thomas D, Lemon SM. Hepatitis C Virus. In: Mandel GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th edition. New York: Churchill Livingstone; 2000. p. 1736-59.
136. Cameron DW, Valdes J, Garber G, et al. Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease [abstract 359]. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998.
137. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999;13:870-1.
138. John L, Marra F, Ensom MHH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacother 2001;35:745-54.
139. Van Heeswijk RPG. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit 2002;24:323-31.
140. Zucker SD, Quin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-6.
141. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr and Hum Retrovirol 1995;8:141-51.
142. Cheeseman SH, Havlir D, McLaughlin MM, et al. High-dose nevirapine: safety, pharmokinetics, and antiviral effect in patients with human immunodeficiency infection. J Infect Dis 1995;171:537-45.
143. Davey RT, Chaitt DG, Reed GF, et al. Randomized, controlled phase I/II trial of combination therapy with delavirdine and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1996;40:1657-64.
144. Adkins JC, Noble S. Efavirenz. Drugs 1998;56:1055-64.
145. Stazcewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.
146. Martinez E, Blanco J, Amaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001;15:1261-8.
147. Sulkowski M, Thomas D, Mehta S, Chaisson RE, Moore RE. Hepatotoxicity associated with nevirapine and efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-9.
148. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:340-5.
149. Boehringer Ingelheim. International Viramune product monograph, Version 3.0. Ingelheim/ Rhein, Germany: Boehringer Ingelheim International GmbH; 2001.
150. Cattelan AM, Eme E, Salatino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999;29:455-6.
151. Cahn P, Johnson M, Nusrat R, Hall D. The 1090 Study Team and P. Robinson. Hepatic safety with nevirapine (NVP) and two nucleosides in patients with advanced HIV infection, from a placebo (PBO) controlled clinical endpoint trail (1090). AIDS 2000;14:511.
152. Johnson S, Chan J, Bennett CL. Hepatotoxicity and prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med 2002;137:146-7.
153. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor. AIDS 2000;14(Suppl 4):S12.
154. HIV and Hepatitis Treatment Advcates. Available at: http://www.hivandhepatitis.com/recent/toxicities/120400.html. Accessed October, 2002.
155. Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine. Int J STD AIDS 2000;11:336-7.
156. Treudler R, Husak R, Raisova M, Orfanos CE, Tebbe B. Efavirenz-induced photoallergic dermatitis in HIV. AIDS 2001;15:1085-7.
157. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000;30:227-8.
158. Verdon R, Six M, Rousselot P, Bazin C. Efavirenz-induced acute eosinophilic hepatitis. J Hepatol 2001;34:783-5.
159. Soriano V, Dona C, Barreiro P, Gonzalez-Lahoz J. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? AIDS 2000;14:1672-3.
160. Clarke S, Harrington P, Barry M, Mulcahy F. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis 2000;31:806-7.
161. Bruno R, Sacchi P, Puoti M, Soriano V, Filice G. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002;97:1598-606.
162. Sulkowski M, Chaisson RE. Gastrointestinal and hepatobiliary manifestations of human immunodeficiency virus infection. In: Mandel GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th edition. New York: Churchill Livingstone; 2000. p. 1426-31.
163. Ferdinand WNM, Wood R, Horban A, et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001;15:2423-9.
164. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. February 4, 2002. p. 16-7. Available in PDF at: http://aidsinfo.nih.gov/guidelines/adult/AAMay23.pdf. Accessed October 2002.
165. Marcus K, Truffa M, Boxwell D, Toemer J. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: Cases from the FDA's Adverse Event Reporting System. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 24-28, 2002.
166. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin Infect Dis 2000;31:167-9.
167. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002;15:23-9.
168. Lafeullade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HCV/HIV coinfection. Lancet 2001;357:280-1.
169. Kakuda T, Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1802-3.
170. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silberman B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001;357:1803-4.
171. Guyader D, Poinsignon Y, Cano Y, Saout L. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol 2002;37:289-91.
172. Johns Hopkins Hospital AIDS Service. Available at: Website Website. http://www.hopkins-aids.edu. Accessed October 2002.
173. Leitze Z, Nadeem A, Choudhary A, Saul Z, Roberts I, Manthous CA. Nevirapine-induced hepatitis treated with corticosteroids? AIDS 1998;12:1115-7.
174. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapine-associated exanthem using slow dose escalation and/or corticosteroids. AIDS 2000;14:2153-7.
175. Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamin administration in an HIV-infected patient on HAART. Int J STD AIDS 2001;12:407-9.
176. Luzatti R, Del Brove P, Di Perri G, Luzzani A, Concia E. Riboflavin and severe lactic acidosis. Lancet 1999;353:901-2.
177. Brinkman K, Vrouenraets S, Kauffman R, Weigel H, Frissen J. Treatment of nucleoside-analog reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000;14:2801-2.
178. Falck-Ytter Y, Younossi Z, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
179. Angulo P. Nonalcoholic Fatty Liver Dis-ease. N Engl J Med 2002;346:1221-31.
180. Tilg H, Diehl AM. Cytokines in Alcoholic and Nonalcoholic Steatohepatitis. N Engl J Med 2000;343:1467-76.
181. Chitturi S, Farrel GC. Etiopathogenesis of Nonalcoholic Steatohepatitis. Semin Liver Dis 2001;21:27-41.
182. Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002;16:2183-93.
183. Ong JP, Younossi Z, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21:266-71.
184. Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001;34:314-20.
185. Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
186. de la Asuncion JG, del Olmo ML, Sastre J, Millian A, Palliardo FV, Vina J. Zidovudine Causes Oxidation of Mitochondrial DNA in Mouse Liver. Hepatology 1999;29:985-7.
187. Yamaguchi T, Katoh I, Kurata S. AZT causes functional & structural destruction of mitochondria, glutathione deficiency & HIV-1 promoter sensitization. Eur J Biochem 2002;269:2782-8.
188. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001;6:777-90.
189. Lai MMC. Hepatitis C virus proteins: Direct link to hepatic oxidative stress, steatosis, carcinogenesis and more. Gastroenterology 2002;122:568-9.
190. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2000;122:366-75.
191. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-infected and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-7.
192. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection:a cohort study. J Acquir Immune Defic Syndr 2000;24:211-7.
193. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-7.
194. Monga HK, Rodriguez-Barradas MC, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-7.
195. Conti S, Masocco M, Pezzotti P, et al. Excess mortality from liver disease and other non-AIDS-related diseases among HIV-infected individuals in Italy. J Acquir Immune Defic Syndr 2002;29:105-7.